Using this model, we observed that biologic disease-modifying antirheumatic drugs were less likely to be switched compared to the majority of other psoriasis therapies, whereas TNF-α inhibitors combined with csDMARDs had a higher switching rate. This evidence concerns the gene TNF and psoriasis.